Abstract
SummaryAL amyloidosis (AL) and monoclonal gammopathy of renal significance (MGRS) are both paraprotein-associated diseases. Both entities are based on a monoclonal paraprotein produced by a clonal plasma-cell population like in monoclonal gammopathy of undetermined significance (MGUS) or by a B-cell population like in low grade lymphoma. Per definition MGUS and low-grade lymphoma do not require treatment. But in rare cases the monoclonal M‑gradient acts as a “toxic” protein inducing severe multimodal organ damage as in AL and MGRS. Urgent treatment is indicated in AL and in MGRS to avoid irreparable loss of organ function or death. No treatment is currently approved in Europe for AL or MGRS. On January 15, 2021 the US Food and Drug Administration approved the monoclonal anti-CD38 antibody for treatment of AL. To minimize the serum M‑gradient concentration, a clone directed therapy as in multiple myeloma or B‑cell malignancies treatment regimens can be applied. In AL, an additional treatment option is under investigation. These special drugs are directed against the typical amyloid-fibrils responsible for deposition formation. An additional and important consideration in this special field of rare diseases is the option of organ transplantation in particular kidney transplantation in MGRS. All these treatment modalities are addressed in this article.
Highlights
In AL and monoclonal gammopathy of renal significance (MGRS), tissue and organ damage are linked to a monoclonal paraprotein [1]
In AL and MGRS, tissue and organ damage are linked to a monoclonal paraprotein [1]
In MGRS [2], renal tissue damage is linked to a monoclonal paraprotein but the pathomechanisms are very diverse and multimodal [3]
Summary
In AL and MGRS, tissue and organ damage are linked to a monoclonal paraprotein [1]. A monoclonal misfolded protein with reduced solubility is produced by either a clonal B-cell population or by a clonal plasma-cell population. This paraprotein, most often clonal free-light-chains, form insoluble fibrils and lead to extracellular depositions. These “toxic” depositions induce tissue damage with loss of organ function In MGRS [2], renal tissue damage is linked to a monoclonal paraprotein but the pathomechanisms are very diverse and multimodal [3]. Because of the high diversity of pathomechanisms and the multitude of paraprotein-associated lesions, a classification system for MGRS was introduced in 2019 [3]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.